Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sjjjtttt, I'm in acummulating mode
henning, significant increase shareholder value ? Can I make a suggestion ? Lower the AS and OS to with 6 billion LOL
I'm loaded, let it ROOOOOOOOOOOCK !
what's the AS and OS on this one ?
out of this pos
jb,
what's a DAT + can you short pinkies ?
you'll like this more ... Financials just published
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010
- Advances Achieved in All Six Bavituximab and Cotara(R) Cancer Clinical Studies - - Total Revenue Increased 345% to $6.75 Million, Avid Revenue Increased 74% and Net Loss Declined 52% Compared to Prior Year Quarter -
TUSTIN, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable prior year quarter. This increase was primarily generated from increased government contract revenue and from increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.
Avid generated manufacturing revenues of $2,070,000 for the first quarter of FY 2010, compared to $1,193,000 for the comparable prior year quarter, an increase of 74%. The increase in Avid revenues reflects increased manufacturing services provided to third-party customers during the quarter. In addition to manufacturing revenues, Peregrine generated revenues from services provided under its contract with the U.S. Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI) to evaluate bavituximab as a potential broad-spectrum treatment for viral hemorrhagic fever infections. Government contract revenues were $4,671,000 for the first quarter of FY 2010, compared to $324,000 for the prior year quarter when the government contract work had just begun.
Total costs and expenses in the first quarter of FY 2010 were $8,940,000, compared to $6,677,000 in the first quarter of FY 2009, an increase of 34%. Costs of contract manufacturing, which increased to $1,073,000 in the first quarter of FY 2010 from $903,000 in the prior year quarter, were directly driven by the increase in Avid revenue. Research and development (R&D) expenses increased to $6,074,000 in the first quarter of FY 2010, compared to $4,068,000 in the prior year quarter, an increase of 49%, primarily due to increased R&D costs incurred under the government contract combined with increased costs associated with the advancement of Peregrine's clinical programs. Selling, general, and administrative (SG&A) expenses increased only slightly in the first quarter of FY 2010 to $1,793,000, compared to $1,706,000 in the first quarter of FY 2009.
The consolidated net loss of $2,428,000 or $0.01 per basic and diluted share in the first quarter of FY 2010 represented a 52% decrease compared to the consolidated net loss of $5,086,000, or $0.02 per basic and diluted share for the same prior year period. At July 31, 2009, the company had $12,778,000 in cash and cash equivalents.
"I am pleased to report that the momentum we achieved in all elements of our business in the last fiscal year has continued into fiscal year 2010," said Steven W. King, president and CEO of Peregrine. "We have continued to successfully advance the bavituximab and Cotara cancer clinical trials that are the key value drivers for Peregrine. Since the start of the new fiscal year, we completed patient enrollment in two bavituximab clinical trials and presented positive interim data from both studies at ASCO, in addition to reporting positive clinical data from our ongoing Cotara clinical studies at the Society of Nuclear Medicine 2009 Annual Meeting. We also continued to make excellent progress in our work under our TMTI government research contract worth up to $44.4 million to develop bavituximab for the treatment of viral hemorrhagic fevers (VHF), while our collaborators at UT Southwestern Medical Center were awarded a significant grant from the National Institute for Allergies and Infectious Diseases (NIAID) for an expanded study of additional PS-targeting antibodies as potential treatments for VHF. The awarding of the new NIAID contract is another important outside validation of the broad-spectrum anti-viral potential of our PS-targeting technology platform."
Mr. King added, "In all three of our bavituximab cancer Phase II trials, bavituximab in combination with chemotherapy has demonstrated encouraging signs of anti-tumor activity in patients with advanced breast and lung cancers. All three trials surpassed the requisite efficacy criteria for expansion of patient enrollment. These trials, along with recent completion of planned enrollment in our U.S. Phase I bavituximab cancer study, are helping to set the stage for advancing bavituximab toward additional clinical trials. As we plan for these trials, we are very pleased to be working with noted cancer clinical researcher Dr. Bruce Chabner, clinical director of Massachusetts General Hospital Cancer Center, who is serving as a clinical advisor on the design of these next clinical trials."
Mr. King continued, "During the first quarter, we completed an agreement with Affitech A/S, sublicensing them certain rights to develop the selective anti-VEGF antibodies produced in an earlier collaboration. This agreement provides us with upfront and potential milestone payments and royalties, and is an excellent example of how we intend to continue leveraging the non-core technologies that are part of Peregrine's asset base. We also reported outstanding financial results for the quarter, growing revenues 345% and reducing our net loss by more than half. Our revenue growth reflects the success of our federal government R&D contract work and continued growth in our contract manufacturing business, Avid. We announced last week that we have expanded the management team at Avid to help manage and sustain this growth."
Mr. King concluded, "These achievements since the end of the last fiscal year have enabled us to continue to build significant value in our oncology clinical pipeline, to grow the value of our contract manufacturing business and to realize immediate value from our bavituximab anti-viral platform through our TMTI government contract work. Planning for the exciting next phase of our bavituximab oncology program has already begun. With seven ongoing clinical trials on track to generate additional data in the coming months, Avid Bioservices focused on continued growth and our government-supported anti-viral research contract proceeding well, we believe Peregrine is well positioned to continue building the momentum we have achieved in the first quarter of this new fiscal year."
FY 2010 Highlights to Date
Bavituximab Anti-Cancer Program
Peregrine reported progress in all four ongoing trials in its bavituximab cancer program, including its three Phase II trials:
-- Completed enrollment of the planned 46 patients in a Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients. As reported in an oral presentation at the 2009 ASCO Annual Meeting, 10 of 14, or 71% of evaluable patients in the initial cohort demonstrated an objective tumor response according to RECIST criteria. These early data from the study compare favorably with historical
EWRC - 13 - 44%
EWRC - I'll settle with 0.01 LOL
EWRC boooooom booooom
EWRC setting up micely for a run + 22%
where can i find the updated filings ?
One heck of a cannnnnndle
YEEEEEEEEEEEEEZ
good run ! will gap tomorrow
SFIO - 8,7 million float - testing starts - news on Friday
utriPure Beverages, Inc. Announces Creation of New Enhanced Water Formulation
NEWPORT BEACH, CA -- (Marketwire) -- 08/14/09 -- NutriPure Beverages, Inc. (PINKSHEETS: NBVG) and its subsidiary XND Technologies, Inc. have developed a new Relaxation formulation to be included in its Nu2O line of nutrient-enhanced bottled water products. "Relaxation in a Bottle" is a vitamin enhanced formula that reduces stress and fatigue and promotes relaxation without drowsiness. In a recent poll published by The Flow/Newsletter/BevNet.com Inc, asking "Which functional claim will help sell the most beverages in 2010," 29% of responders answered "Relaxation," the largest single category mentioned, ahead of "Calorie Burning," "More Energy," Brain Power," and "Other."
The Relaxation product is the 13th formulation in the Nu2O line, along with Energy, Complete, Immune, Sports, Joint, Weight Control, Heart Health, Brain Stimulation, Digestive Health, Eye Health, Beauty, and a Prehydration Workout Drink. The company plans to launch the Nu2O line with three products by year's end and release at least 10 additional products over the following 12 months.
XND CEO Steve Nicholas commented, "This is another reaffirmation of NutriPure's commitment to always remain on the cutting edge of current developments in bottled water and energy drinks. As we focus on our upcoming rollout, our scientific team is continuously reviewing all our formulations and more will be added when they become available and as the market demands."
Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office
* Press Release
* Source: Hard to Treat Diseases
* On Wednesday August 12, 2009, 10:32 am EDT
o
Buzz up! 0
o Print
SHENZHEN, China, Aug. 12 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - further to the Company news release of July 9, 2009 http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds today at 10:30AM EST that the Company has completed the necessary filings required to correct the ownership of its intellectual property (IP) rights.
Having performed an extensive audit and investigation on five (5) issued patents, HTDS finds that the Company should have been assigned full ownership of the patents. Filings were made today with the U.S. Patent and Trademark Office that formalize, and secure HTTD's ownership and rights to the patents. http://www.uspto.gov
In summary, The IP rights are being utilized by a fully reporting OTCBB publicly traded company. As a result of HTDS IP rights, this company has raised substantial monies in equity financing, constructed an operating plant that generates revenue, is in the process of purchasing parcels of property in various States in order to construct additional plants. It also has had numerous industrial bonds approved for several million dollars each.
The issuer for the time being has elected not to name the OTCBB publicly traded company that is utilizing its rights, however HTDS has placed the OTCBB company on formal notice. Notwithstanding, HTDS management is looking towards a mutually amicable resolution of this matter. HTDS is of the opinion that this OTCBB company got off to a great start, primarily because of these patents, which rightfully belong to HTDS. HTDS takes the position that there is no good or valid dispute that these IP rights belong to anyone else but HTDS. The following SEC filing http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=652915 dated June 2, 2000 together with today's filings with the U.S. Patent and Trademark Office http://www.uspto.gov are self explanatory and apparent on their face.
The issuer expects a "knee jerk" reaction by the OTCBB Company, including the standard form letter type denials issued by their barristers, a denouncement and a host of other panic stricken immediate type reactions. HTDS management intentions are neither to harm the OTCBB operations nor to destabilize OTCBB shareholders value. Instead, it will seek a harmonious "WIN-WIN" solution. Once the rights are finalized, HTDS is positioning itself to aggressively move the recycling industry to a higher level, with a separate recycling operating division inside HTDS; which should not disrupt HTDS' primary Bio Chem and Vaccine business. In the event the OTCBB utilizing HTDS rights is willing to cooperate, HTDS may very well have found a new partner. HTDS management is also mindful that refusal of this infringement may leave the HTDS management with no other alternative but to attorn these IP rights and to appoint an interim HTDS management to assume the recycling operations.
The management of HTDS is not ruling out any options at this point. Either way, once HTDS assumes control, the management anticipates gross revenue exceeding $250 million within two years.
Resolutions and a decision are expected shortly.
In other company news, Mr Terry Yuan CEO of HTDS said "We are delighted by the recent events taking place at HTDS. We wish to take this opportunity to advise our shareholders, and followers that some of the aforementioned revenue figures of both this release and the one of July 9, 2009 were derived directly from the OTCBB Company SEC Filings, and figures taken from OTCBB Company confidential brochures furnished to its accredited investors. We have in our possession, and we intend to file with the Pink Sheets shortly the USPTO corrective filings, the FedEx delivery and HTDS notice of infringements served upon the OTCBB directors, officers, and its auditors in the event of failed mutually acceptable resolution to the IP rights.
At HTDS and here in China we continue business as usual focusing on daily operations. Our extensive audit and investigation on these five (5) issued patents started months ago. There are many outstanding follow up matters which we intend to fully follow up with such as: CEO message from both operating subsidiaries Slavica Bio Chem in Serbia and Mellow Hope in China, our financial filings due shortly, pending legal opinion on the filed adequate disclosure, update on the slander lawsuit where HTDS is one of several beneficiaries, forward guidance, our pennies plus set targeted share price to name a few. Over the course of time we will be providing all of these updates on a timely basis including new, and pending contracts, and progresses we made so far. This is truly an exciting time to be part of the HTDS organization, and we appreciate all of our shareholders and followers sharing that joy mutually with us"
Additional details and information will be released as they become available, via regular news releases or via Pink Sheets filing service.
Safe Harbor Statement:
THRR - 0019's up
THRR - nice call
THRR - booom
no, I'm Belgian - thx for the explanation !!
what's the UL clearance ?
this one is too long in my portfolio - BUUUUY IIITTTTTT
GNVC - 2nd contract in 2 days
GAITHERSBURG, Md., July 29 /PRNewswire-FirstCall/ -- GenVec, Inc. (NASDAQ: GNVC) announced today that it has received a Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the company's malaria vaccine program.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )
"We appreciate the support this grant offers GenVec. This funding supports the advancement of GenVec technology by moving GenVec into the antigen discovery phase of vaccine development," said Dr. Joseph Bruder, head of GenVec's malaria program.
This grant, valued at approximately $600,000 over two years, will be used to identify new immunogenic antigens for malaria vaccine development. Using the funding from this grant, GenVec will be collaborating with the U.S. Naval Medical Research Center (NMRC) to apply its adenovector technology to the development of malaria vaccine candi
GNVC - 2nd contract in 2 days
GAITHERSBURG, Md., July 29 /PRNewswire-FirstCall/ -- GenVec, Inc. (NASDAQ: GNVC) announced today that it has received a Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the company's malaria vaccine program.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )
"We appreciate the support this grant offers GenVec. This funding supports the advancement of GenVec technology by moving GenVec into the antigen discovery phase of vaccine development," said Dr. Joseph Bruder, head of GenVec's malaria program.
This grant, valued at approximately $600,000 over two years, will be used to identify new immunogenic antigens for malaria vaccine development. Using the funding from this grant, GenVec will be collaborating with the U.S. Naval Medical Research Center (NMRC) to apply its adenovector technology to the development of malaria vaccine candi
GAITHERSBURG, Md., July 29 /PRNewswire-FirstCall/ -- GenVec, Inc. (NASDAQ: GNVC) announced today that it has received a Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the company's malaria vaccine program.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )
"We appreciate the support this grant offers GenVec. This funding supports the advancement of GenVec technology by moving GenVec into the antigen discovery phase of vaccine development," said Dr. Joseph Bruder, head of GenVec's malaria program.
This grant, valued at approximately $600,000 over two years, will be used to identify new immunogenic antigens for malaria vaccine development. Using the funding from this grant, GenVec will be collaborating with the U.S. Naval Medical Research Center (NMRC) to apply its adenovector technology to the development of malaria vaccine candi
looking great this one
I am - bought in at 64
well already some weeks LOL
in EWRC
This man stated that the secret to his age was 'cigarettes, wisky and wild women' !!!
Respect to this man as he aided during the liberation of my country (I'm Belgian) not once, but twice !!!
DDA
I think we did most of the buyng of the big seller LOL
Carlito,
I've been adding nicely today - it can go to that 0.12 now LOL
you know more ?
I don't see it ?
nope, but guess it's above 1 billion based on the last days of trading
Carlito,
Well spoken, back to lurking mode LOL
still I wonder ..
could u pls explain ? thx
Carlito,
nice one
dda